CClinicalTrials.gg
CompletedNCT03115580ORBID-FFRUpdated May 14, 2020Results posted

Side Branch FFR After Provisional Stenting

An interventional study of Rotational atherectomy and Cutting Balloon Angioplasty in Coronary Artery Disease, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-14.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to predict any changes in the side branch after stenting the main branch blood vessel using three dimensional intravascular images. (Frequency domain optical coherence tomography FD OCT).

Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels. These images will be used before and after implanting the stent in the main blood vessel. Fractional Flow Reserve (FFR) test, which makes it possible for the interventional cardiologist to calculate blood flow across an area of a coronary artery, will be done after stenting and will help to determine if there are any changes in the side branch blood flow.

Read the detailed description

Coronary artery bifurcation lesion is a common lesion subset in PCI accounting for 15-20% of the total number of interventions. Treatment of coronary artery bifurcation lesions represents a challenging area in interventional cardiology. When compared with non-bifurcation interventions, bifurcation interventions have a lower rate of procedural success, higher procedural costs, longer hospitalization and a higher clinical and angiographic restenosis. Factors contributing to this adverse outcome include limitations of angiography in assessment of side-branch (SB) disease severity and the lack of established angiographic predictors of SB patency and lumen compromise. Better understanding of the underlying plaque morphology and plaque composition may facilitate more effective treatment of bifurcation lesions.

Intravascular imaging has provided new understanding of mechanisms associated with SB compromise following bifurcation PCI. Plaque shift has been traditionally considered as the principal mechanism for side-branch compromise after main vessel intervention. Rotational atherectomy(RA) has been advocated for the treatment of bifurcation lesions, since it can effectively remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the "snow plow" effect. Intravascular ultrasound (IVUS) has been used for guidance in bifurcation lesions, aiding the visualization of plaque morphology at the main vessel and the side-branches and helping the selection of stent size and length as well as the selection of stenting strategy. However, due to the low spatial resolution of IVUS, all attempts for three-dimensional visualization have only focused on visualization of the luminal contour and not on the vessel morphology or the vessel-stent interaction. Optical coherence tomography (OCT) has \~10 times higher resolution than IVUS, which allows precise evaluation of the microstructure of the vessel wall including lipid pool, fibrous cap, calcification, and thrombus. OCT has been shown to constitute a valuable tool for PCI guidance and also the utility of three-dimensional (3D) renderings for assessing the mechanism of side-branch compromise following intervention in bifurcation lesions. The recent development of OCT with online 3D reconstruction allows the operator to obtain a 3D visualization of the lesion and may provide a unique tool for guidance during complex bifurcation PCI and potentially improve stenting results. 3D OCT has been used to visualize jailed side branches after implantation of bioresorbable scaffolds in the main branch and develop a new classification system based on the number of SB compartments. In addition, its potential clinical application in guiding the rewiring of the distal compartment of the SB ostium (jailed with stent struts after MB stenting) to minimize the risk of floating struts was demonstrated It is important to note that while OCT, 3D-OCT, and 3D-QCA (such as that used in the ORBID trial) are imaging modalities that can be used to answer important research questions, their wide-spread adoption in daily clinical practice has been very limited. Intravascular ultrasound (IVUS) is used more frequently as part of a PCI guidance strategy in daily clinical practice.

Fractional flow reserve (FFR) is a pressure-derived, lesion specific index used to determine the functional significance of coronary artery stenosis. Several studies showed that FFR is a safe and feasible method to assess the significance of an ostial SB stenosis after provisional stenting. Quantitative coronary angiography (QCA) has been shown to be unreliable in assessing the functional significance of SB after stent implantation in MV (the area under the curve 0.64, 41.5% sensitivity and 83.1% specificity) suggesting that treatment decisions for jailed SB should not be based on angiographic findings alone. A recent report demonstrated a better ability of post-PCI 3D-OCT to predict the functional significance for SB ostial lesions caused by a jailed SB outcome.

A previous study (ORBID) of 30 patients was done at Mount Sinai Hospital and aimed to identify the predictors of side branch (SB) ostial stenosis developed after provisional stenting of the main vessel (MV) using Optical Coherence Tomography (OCT). The study Showed that High lipid content of the MV lesion and a contralateral location of lipid in the bifurcation area may contribute to SBOS after provisional stenting.

The objective of this study is to analyze the incidence of SB compromise after provisional main vessel stenting in calcified bifurcation lesions of CAD patients, determine the incidence and OCT predictors of functionally significant SB stenosis defined as FFR ≤ 0.8 and to compare the FFR values with 3D-OCT measurements of jailed SB ostium after MV stenting.

Stable CAD patients with bifurcation lesions in whom provisional stenting strategy is planned, who have moderate or severe calcification in the main vessel lesion identified by angiography, SB stenosis 30-70% and SB reference diameter > 2mm will be enrolled in the study.

Moderate calcification will be defined as radiopaque density observed only during the cardiac cycle and typically involving only one side of the vascular wall, and severe calcification will be defined as radiopaque density noted without cardiac motion prior to contrast injection and involving both sides of the arterial wall. After completion of diagnostic angiogram and confirmation of subject eligibility, subjects will be randomly assigned to Rotational Atherectomy (RA) or Cutting Balloon Angioplasty (CBA)/Percutaneous Transluminal Coronary Angioplasty (PTCA) group in a 1:1 fashion.

Patients in both groups will undergo PCI with stent implantation according to current standards of care. Lesion preparation including lesion pre-dilation, scoring or sculpting balloon angioplasty, and use of atherectomy and protection devices will be performed at the operator's discretion, followed by MV stenting. The operator will also decide in both groups about the length and size of the implanted stent. Procedural optimization, such as post-dilation or additional stent implantation will be performed based only on the angiographic findings, according to the discretion of the operator.

02

Conditions studied

03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 955 are open to participants now.

This study's enrollment of 71 is below the median of 123 across 3,435 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Icahn School of Medicine at Mount Sinai is the lead sponsor of 764 studies on the registry; 181 are open to participants now.

Of its 121 completed or terminated interventional studies of FDA-regulated products, 82 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients over 18 years of age presenting with stable coronary artery disease.
  • Patients must have a clinical indication for coronary intervention.
  • Creatinine Kinase Myocardial-Band Isoenzyme (CK-MB) must be less than or equal to the upper limit of lab normal (ULN) value within eight hours prior to the procedure.
  • The target lesion must be a de novo calcified bifurcation coronary lesion that hasn't been previously treated with any interventional procedure for which provisional main vessel stenting strategy is planned after reviewing angiogram.
  • The target vessel must be a native coronary artery with

    1. stenosis ≥70% and \<100%, or
    2. Stenosis ≥50% and \<70% with evidence of clinical ischemia via positive stress test, or FFR ≤ 0.8, or IVUS or OCT minimal lumen area ≤ 4.0 mm2.
  • The target lesion should have SB DS 30 - 70%.
  • The target main vessel reference diameter must be ≥2.5 mm and ≤ 4.0 mm.
  • The SB reference diameter must be > 2 mm by coronary angiogram.
  • The target vessel must have a Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 at baseline.

Exclusion criteria

Exclusion Criteria:

  • Patients with ostial left main artery lesions or ostial right coronary artery lesions
  • Female patients with child bearing potential not taking adequate contraceptives or currently breastfeeding
  • Known allergy to acetylsalicylic acid or clopidogrel.
  • Planned surgery within 12 months.
  • History of bleeding diathesis
  • Major surgery within 15 days
  • Life expectancy \< 12 months.
  • Patients with kidney dysfunction (CrCl\<30)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Active comparator
    Rotational atherectomy

    Rotational atherectomy (RA)

    Device: Rotational atherectomy

  • Active comparator
    CBA/PTCA

    Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)

    Device: Cutting Balloon Angioplasty

Interventions

  • DeviceRotational atherectomy

    Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the "snow plow" effect.

    Also known as: RA

  • DeviceCutting Balloon Angioplasty

    Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon

    Also known as: CBA

06

What researchers measure

Primary outcomes

  1. Number of Participants With Side Branch Compromise

    Number of participants with Side Branch (SB) compromise which is defined as SB DS \> 70%, or dissection or TIMI \< 3

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants With SB Dissection

    Number of participants with SB dissection

    Time frame: Day 1

  2. Number of Participants With TIMI < 3

    Number of participants with TIMI flow grade \< 3

    Time frame: Day 1

  3. Number of Participants With SB DS >70%

    Number of participants with Side Branch Diameter Stenosis (DS) \> 70%

    Time frame: Day 1

  4. Number of Participants With FFR Device Success

    Number of Participants with successfully deliver Fractional Flow Reserve (FFR) wire to desired SB distal segment

    Time frame: Day 1

  5. Number of Patients With FFR Wire Workhorse Capability

    FFR Wire Workhorse Capability - Number of patients in which FFR wire was able to serve as rail to deliver additional interventional devices to target SB lesion

    Time frame: Day 1

07

Results

Posted May 8, 2020

Participant flow

Participants enrolled between May 2017 and March 2019.

Participant flow — Overall Study
MilestoneRotational AtherectomyCBA/PTCA
Started3536
Completed3536
Not completed00

Outcome measures

PrimaryNumber of Participants With Side Branch Compromise

Number of participants with Side Branch (SB) compromise which is defined as SB DS \> 70%, or dissection or TIMI \< 3

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Side Branch Compromise
ParticipantsRotational AtherectomyCBA/PTCA
Number of Participants With Side Branch Compromise79
SecondaryNumber of Participants With SB Dissection

Number of participants with SB dissection

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With SB Dissection
ParticipantsRotational AtherectomyCBA/PTCA
Number of Participants With SB Dissection10
SecondaryNumber of Participants With TIMI < 3

Number of participants with TIMI flow grade \< 3

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With TIMI < 3
ParticipantsRotational AtherectomyCBA/PTCA
Number of Participants With TIMI < 335
SecondaryNumber of Participants With SB DS >70%

Number of participants with Side Branch Diameter Stenosis (DS) \> 70%

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With SB DS >70%
ParticipantsRotational AtherectomyCBA/PTCA
Number of Participants With SB DS >70%24
SecondaryNumber of Participants With FFR Device Success

Number of Participants with successfully deliver Fractional Flow Reserve (FFR) wire to desired SB distal segment

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With FFR Device Success
ParticipantsRotational AtherectomyCBA/PTCA
Number of Participants With FFR Device Success2827
SecondaryNumber of Patients With FFR Wire Workhorse Capability

FFR Wire Workhorse Capability - Number of patients in which FFR wire was able to serve as rail to deliver additional interventional devices to target SB lesion

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Patients With FFR Wire Workhorse Capability
ParticipantsRotational AtherectomyCBA/PTCA
Number of Patients With FFR Wire Workhorse Capability00

Adverse events

Collected over 1 Day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotational Atherectomy0/35 (0%)0/35 (0%)3/35 (8.6%)
CBA/PTCA0/36 (0%)0/36 (0%)1/36 (2.8%)
Most frequent other events
Most frequent other events
EventRotational AtherectomyCBA/PTCA
LM dissection with contrast injectingSurgical and medical procedures1/350/36
Right CFA access side bleedingSurgical and medical procedures1/350/36
Dissection MinorCardiac disorders1/350/36
Side branch closureCardiac disorders1/350/36
Staged PCI pf p:CS-OM1Cardiac disorders1/350/36
Chest PainCardiac disorders0/351/36
Transient sidebranch closingCardiac disorders0/351/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rotational AtherectomyCBA/PTCATotal
Mean67.8 ± 10.566.6 ± 9.967.2 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Rotational AtherectomyCBA/PTCATotal
Female71421
Male282250
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Rotational AtherectomyCBA/PTCATotal
Count of participants——0
Diabetes Mellitus
Diabetes Mellitus(Participants)Rotational AtherectomyCBA/PTCATotal
Count of participants111425
Hypertension
Hypertension(Participants)Rotational AtherectomyCBA/PTCATotal
Count of participants283058
Hyperlipidemia
Hyperlipidemia(Participants)Rotational AtherectomyCBA/PTCATotal
Count of participants322961
Current smoker
Current smoker(Participants)Rotational AtherectomyCBA/PTCATotal
Count of participants516
Previous myocardial infarction
Previous myocardial infarction(Participants)Rotational AtherectomyCBA/PTCATotal
Count of participants7310

7 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai and the Mount Sinai Hospital
    New York, New York 10029, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 19, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03115580
Lead sponsor
Icahn School of Medicine at Mount Sinai
Responsible party
Annapoorna Kini (Director Cardiac Cath lab, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Apr 14, 2017
Start date
May 2, 2017
Primary completion
Mar 26, 2019
Completion
Mar 26, 2019
Results posted
May 8, 2020
Last update
May 14, 2020

Study contacts

Annapoorna Kini, MD, MRCO, FACC
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion